Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cost of Revenue (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Cost of Revenue data on record, last reported at $330.2 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 230.64% year-over-year to $330.2 million; the TTM value through Dec 2025 reached $363.8 million, up 77.07%, while the annual FY2025 figure was $363.8 million, 1.6% up from the prior year.
  • Cost of Revenue reached $330.2 million in Q4 2025 per AMPH's latest filing, up from -$66.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $330.2 million in Q4 2025 and bottomed at -$66.2 million in Q3 2025.
  • Average Cost of Revenue over 5 years is $64.5 million, with a median of $63.1 million recorded in 2022.
  • Peak YoY movement for Cost of Revenue: soared 1322.57% in 2022, then tumbled 835.79% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $64.7 million in 2021, then skyrocketed by 262.04% to $234.1 million in 2022, then tumbled by 96.32% to $8.6 million in 2023, then soared by 1058.78% to $99.9 million in 2024, then soared by 230.64% to $330.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $330.2 million in Q4 2025, -$66.2 million in Q3 2025, and $87.9 million in Q2 2025.